Skip to main content
. Author manuscript; available in PMC: 2016 Aug 26.
Published in final edited form as: J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):171–176. doi: 10.1097/QAI.0000000000000942

Figure 1.

Figure 1

The Kaplan-Meier plot shows the cumulative incidence of patients free of failure events per the as-treated analysis according to the anchor-drug class (bPI, boosted protease inhibitor; INSTI, integrase strand transfer inhibitor; or NNRTI, nonnucleoside reverse-transcriptase inhibitor). The as-treated analysis failure outcome was virological failure (VF), defined as not reaching an undetectable HIV-1 RNA level by 24 weeks, virological rebound, and regimen switching during viremia. The P value was calculated by the log-rank test.